![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD55 |
Gene summary for CD55 |
![]() |
Gene information | Species | Human | Gene symbol | CD55 | Gene ID | 1604 |
Gene name | CD55 molecule (Cromer blood group) | |
Gene Alias | CHAPLE | |
Cytomap | 1q32.2 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P08174 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1604 | CD55 | CA_HPV_1 | Human | Cervix | CC | 7.14e-04 | -2.33e-01 | 0.0264 |
1604 | CD55 | N_HPV_2 | Human | Cervix | N_HPV | 3.11e-02 | 2.89e-01 | -0.0131 |
1604 | CD55 | H2 | Human | Cervix | HSIL_HPV | 1.74e-08 | 4.29e-01 | 0.0632 |
1604 | CD55 | L1 | Human | Cervix | CC | 3.04e-06 | -3.93e-01 | 0.0802 |
1604 | CD55 | T2 | Human | Cervix | CC | 2.37e-17 | 9.46e-01 | 0.0709 |
1604 | CD55 | AEH-subject1 | Human | Endometrium | AEH | 9.18e-06 | 4.01e-01 | -0.3059 |
1604 | CD55 | AEH-subject2 | Human | Endometrium | AEH | 2.11e-02 | 2.11e-01 | -0.2525 |
1604 | CD55 | AEH-subject4 | Human | Endometrium | AEH | 4.07e-06 | 3.90e-01 | -0.2657 |
1604 | CD55 | AEH-subject5 | Human | Endometrium | AEH | 4.18e-18 | 6.47e-01 | -0.2953 |
1604 | CD55 | EEC-subject3 | Human | Endometrium | EEC | 5.85e-10 | 3.78e-01 | -0.2525 |
1604 | CD55 | EEC-subject4 | Human | Endometrium | EEC | 1.37e-06 | 3.64e-01 | -0.2571 |
1604 | CD55 | GSM5276934 | Human | Endometrium | EEC | 9.58e-07 | 3.87e-01 | -0.0913 |
1604 | CD55 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.48e-07 | -3.37e-01 | -0.1869 |
1604 | CD55 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.98e-08 | -2.73e-01 | -0.1875 |
1604 | CD55 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.29e-07 | -3.10e-01 | -0.1883 |
1604 | CD55 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 6.23e-04 | -1.37e-01 | -0.1934 |
1604 | CD55 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.73e-15 | 7.71e-02 | -0.1917 |
1604 | CD55 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.84e-15 | 1.05e-01 | -0.1916 |
1604 | CD55 | LZE5T | Human | Esophagus | ESCC | 3.41e-10 | 1.73e+00 | 0.0514 |
1604 | CD55 | LZE21D1 | Human | Esophagus | HGIN | 1.51e-03 | -3.54e-01 | 0.0632 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007121914 | Oral cavity | EOLP | cellular response to molecule of bacterial origin | 39/2218 | 221/18723 | 6.97e-03 | 3.39e-02 | 39 |
GO:00024604 | Oral cavity | EOLP | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 58/2218 | 356/18723 | 7.27e-03 | 3.52e-02 | 58 |
GO:00027203 | Oral cavity | EOLP | positive regulation of cytokine production involved in immune response | 15/2218 | 65/18723 | 7.93e-03 | 3.76e-02 | 15 |
GO:00024566 | Oral cavity | EOLP | T cell mediated immunity | 22/2218 | 109/18723 | 8.31e-03 | 3.91e-02 | 22 |
GO:00357391 | Oral cavity | EOLP | CD4-positive, alpha-beta T cell proliferation | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
GO:20005611 | Oral cavity | EOLP | regulation of CD4-positive, alpha-beta T cell proliferation | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
GO:00027021 | Oral cavity | EOLP | positive regulation of production of molecular mediator of immune response | 23/2218 | 117/18723 | 9.76e-03 | 4.42e-02 | 23 |
GO:00725032 | Oral cavity | EOLP | cellular divalent inorganic cation homeostasis | 75/2218 | 486/18723 | 9.77e-03 | 4.42e-02 | 75 |
GO:00027031 | Oral cavity | EOLP | regulation of leukocyte mediated immunity | 39/2218 | 226/18723 | 1.01e-02 | 4.53e-02 | 39 |
GO:001603218 | Prostate | BPH | viral process | 147/3107 | 415/18723 | 4.46e-21 | 5.52e-18 | 147 |
GO:001905818 | Prostate | BPH | viral life cycle | 112/3107 | 317/18723 | 2.87e-16 | 5.54e-14 | 112 |
GO:005212618 | Prostate | BPH | movement in host environment | 64/3107 | 175/18723 | 1.28e-10 | 7.47e-09 | 64 |
GO:004440318 | Prostate | BPH | biological process involved in symbiotic interaction | 90/3107 | 290/18723 | 6.98e-10 | 3.25e-08 | 90 |
GO:005170118 | Prostate | BPH | biological process involved in interaction with host | 69/3107 | 203/18723 | 9.94e-10 | 4.56e-08 | 69 |
GO:004578518 | Prostate | BPH | positive regulation of cell adhesion | 120/3107 | 437/18723 | 5.22e-09 | 1.90e-07 | 120 |
GO:004440918 | Prostate | BPH | entry into host | 54/3107 | 151/18723 | 8.66e-09 | 2.96e-07 | 54 |
GO:004671818 | Prostate | BPH | viral entry into host cell | 52/3107 | 144/18723 | 1.11e-08 | 3.68e-07 | 52 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:00026839 | Prostate | BPH | negative regulation of immune system process | 100/3107 | 434/18723 | 2.83e-04 | 2.20e-03 | 100 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541620 | Cervix | CC | Viral myocarditis | 27/1267 | 60/8465 | 2.43e-08 | 3.57e-07 | 2.11e-07 | 27 |
hsa05416110 | Cervix | CC | Viral myocarditis | 27/1267 | 60/8465 | 2.43e-08 | 3.57e-07 | 2.11e-07 | 27 |
hsa0541624 | Cervix | HSIL_HPV | Viral myocarditis | 14/459 | 60/8465 | 2.70e-06 | 4.95e-05 | 4.00e-05 | 14 |
hsa04640 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa0541634 | Cervix | HSIL_HPV | Viral myocarditis | 14/459 | 60/8465 | 2.70e-06 | 4.95e-05 | 4.00e-05 | 14 |
hsa046401 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa0541643 | Cervix | N_HPV | Viral myocarditis | 14/349 | 60/8465 | 9.77e-08 | 1.90e-06 | 1.48e-06 | 14 |
hsa046402 | Cervix | N_HPV | Hematopoietic cell lineage | 13/349 | 99/8465 | 1.98e-04 | 1.74e-03 | 1.36e-03 | 13 |
hsa0541653 | Cervix | N_HPV | Viral myocarditis | 14/349 | 60/8465 | 9.77e-08 | 1.90e-06 | 1.48e-06 | 14 |
hsa046403 | Cervix | N_HPV | Hematopoietic cell lineage | 13/349 | 99/8465 | 1.98e-04 | 1.74e-03 | 1.36e-03 | 13 |
hsa0541625 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa05416111 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa0541626 | Endometrium | EEC | Viral myocarditis | 28/1237 | 60/8465 | 2.81e-09 | 5.77e-08 | 4.30e-08 | 28 |
hsa0541635 | Endometrium | EEC | Viral myocarditis | 28/1237 | 60/8465 | 2.81e-09 | 5.77e-08 | 4.30e-08 | 28 |
hsa0541630 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa05416114 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa0541616 | Lung | IAC | Viral myocarditis | 21/1053 | 60/8465 | 5.30e-06 | 1.57e-04 | 1.04e-04 | 21 |
hsa0541617 | Lung | IAC | Viral myocarditis | 21/1053 | 60/8465 | 5.30e-06 | 1.57e-04 | 1.04e-04 | 21 |
hsa0541622 | Lung | AIS | Viral myocarditis | 19/961 | 60/8465 | 2.01e-05 | 4.08e-04 | 2.61e-04 | 19 |
hsa0541632 | Lung | AIS | Viral myocarditis | 19/961 | 60/8465 | 2.01e-05 | 4.08e-04 | 2.61e-04 | 19 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | DCIS |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | IDC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | CC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | MSI-H |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | MSS |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | AEH |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | EEC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Esophagus | ESCC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | GC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | Precancer |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | HNSCC | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | HNSCC | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD55 | SNV | Missense_Mutation | rs752481959 | c.509N>A | p.Arg170Gln | p.R170Q | protein_coding | tolerated(0.55) | benign(0.072) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
CD55 | SNV | Missense_Mutation | novel | c.929N>T | p.Ser310Leu | p.S310L | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-E9-A2JT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
CD55 | SNV | Missense_Mutation | c.940C>G | p.Gln314Glu | p.Q314E | protein_coding | deleterious(0.01) | benign(0.033) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
CD55 | SNV | Missense_Mutation | rs143471404 | c.992N>T | p.Thr331Ile | p.T331I | protein_coding | tolerated(0.17) | benign(0.035) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
CD55 | SNV | Missense_Mutation | novel | c.707N>A | p.Ile236Asn | p.I236N | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD55 | SNV | Missense_Mutation | c.385T>C | p.Cys129Arg | p.C129R | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CD55 | SNV | Missense_Mutation | c.466G>A | p.Glu156Lys | p.E156K | protein_coding | deleterious(0.05) | possibly_damaging(0.826) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CD55 | SNV | Missense_Mutation | rs756646491 | c.389N>A | p.Arg130His | p.R130H | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD55 | SNV | Missense_Mutation | c.967N>T | p.Pro323Ser | p.P323S | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CD55 | SNV | Missense_Mutation | c.589N>G | p.Phe197Val | p.F197V | protein_coding | tolerated(1) | benign(0.013) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | PD-98059 | CHEMBL35482 | 11528371 | |
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | PAT-SC1 | |||
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | ETHANOL | ALCOHOL | 17383432 | |
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | COXSACKIEVIRUS TYPE A21 | |||
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | Coxsackievirus A21 | |||
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | RETINOIC ACID | 15668483 | ||
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | INTERLEUKIN-8 | 14723618 | ||
1604 | CD55 | DRUGGABLE GENOME, CELL SURFACE | ONYVAX-105 (105AD7) |
Page: 1 |